Mounjaro®
Starting from £179.99/mo
Start journey Learn moreEach Mounjaro KwikPen contains four doses, not five. The pen is designed for once-weekly use over a four-week period, so one pen covers a single month of treatment. There is no fifth dose — and if the device appears to have liquid left after the fourth injection, that residual is intentional and not a usable dose. Mounjaro is a prescription-only medicine; a GPhC-registered prescriber must assess your suitability before it can be dispensed.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The Mounjaro KwikPen holds four pre-measured weekly doses. Eli Lilly manufactures the device this way so that a single pen lines up with a four-week prescribing cycle. The pen itself tracks how many injections remain via a dose indicator, and it locks permanently after the fourth use.
The idea that there might be a fifth dose circulates because people notice the pen still feels or looks like it contains liquid after that fourth injection. It does, but that residual fluid is a calculated overfill built into the cartridge to guarantee four accurate doses reach the needle tip. It is not an extractable fifth dose, and attempting to use it risks getting an incomplete or inaccurate amount of medicine. The NHS tirzepatide medicines page advises following the Patient Information Leaflet precisely and using the pen only as directed.
If you are unsure how many injections your pen has left, the indicator window on the device shows the remaining count. If it reads zero, the pen is finished, even if it does not feel completely empty. Our detailed guide to why there is a dose left in your Mounjaro pen explains exactly what that residual liquid is and why it cannot be used. For a fuller picture of the strengths available across the Mounjaro range, the full Mounjaro dose guide covers each step in detail.
No. The residual liquid remaining after four injections is a manufacturing overfill, sometimes called dead volume. Every pre-filled injectable device includes a small buffer to ensure the labelled doses are fully delivered through the needle; without it, the final injection could be short-measured.
This is a standard feature of pre-filled pen technology, not a quirk of Mounjaro specifically. Some people assume they have accidentally skipped a dose or that the device has malfunctioned. Neither is true. The pen's internal plunger mechanism physically cannot advance further once the fourth dose is complete, and the auto-lock engages at that point.
If you genuinely believe you may have missed a dose earlier in the pen's cycle, that is a different question, one best answered by your prescriber or by the Patient Information Leaflet, which sets out what to do depending on how much time has passed. Our guide to how Mounjaro pen doses work goes into more detail on the mechanics. Disposal after the fourth dose matters too: used pens should go into a sharps container, not the household bin.
The auto-lock is a deliberate safety mechanism. Once the fourth injection is complete, the plunger cannot be re-advanced, and the needle shield stays retracted. This prevents accidental re-use, needle-stick injury and any attempt to extract residual liquid, which would involve removing a needle, which is both unsafe and unnecessary.
In practical terms: when the dose counter shows zero, the pen has done its job. Cap it, place it in a sharps disposal bin, and start a fresh pen for the next four weeks. A new pen should be taken from the fridge and allowed to reach room temperature before use, the exact window is in the leaflet, so always check there rather than relying on a general figure. If you are thinking about how cost is structured across monthly supplies, our Mounjaro cost context page explains what a legitimate price typically covers in the UK private market.
Patients sometimes ask a question our prescribers hear fairly often: whether you can share the remaining liquid between household members. The answer is an absolute no, each pen is prescribed for a named individual, is a single-patient device, and sharing a used pen carries serious infection risks.
No licensed UK Mounjaro presentation contains more than four doses per pen. The KwikPen format is consistent across all six UK strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg): four weekly doses per pen, one pen per four-week supply. There is no multi-month or five-dose version available through the licensed UK supply chain.
You may occasionally encounter online content describing compounded or unlicensed versions of tirzepatide sold in different vial or cartridge configurations. These are not the same product as licensed Mounjaro; they are not regulated by the MHRA, and their dose accuracy cannot be verified. The MHRA has warned publicly about counterfeit and unlicensed weight-loss injectables circulating online, some of which have caused harm. If a listing describes a Mounjaro pen with five or more doses, treat that as a red flag. You can also read our overview of tirzepatide 5mg from Bioamino Labs to understand how unlicensed compounded tirzepatide products differ from regulated Mounjaro. You can verify any UK online pharmacy at the GPhC pharmacy register.
For anyone who wants to understand more about how the titration schedule works across pens and months, the Mounjaro treatment overview and our clinical team can help clarify what a supervised programme looks like in practice. If you have specific questions about your own pen or supply, our support team is available seven days a week.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.